3.55
0.10 (2.90%)
| Penutupan Terdahulu | 3.45 |
| Buka | 3.43 |
| Jumlah Dagangan | 1,032,053 |
| Purata Dagangan (3B) | 1,634,452 |
| Modal Pasaran | 1,305,517,184 |
| Harga / Pendapatan (P/E Ke hadapan) | 370.37 |
| Harga / Jualan (P/S) | 2.76 |
| Harga / Buku (P/B) | 2.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -67.28% |
| Margin Operasi (TTM) | -78.39% |
| EPS Cair (TTM) | -1.17 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -27.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 71.85% |
| Nisbah Semasa (MRQ) | 5.96 |
| Aliran Tunai Operasi (OCF TTM) | 6.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 9.81 M |
| Pulangan Atas Aset (ROA TTM) | -4.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -44.32% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Maravai LifeSciences Holdings, | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.38 |
|
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.21% |
| % Dimiliki oleh Institusi | 89.67% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tejara Capital Ltd | 31 Dec 2025 | 3,020,209 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |